ADPT
Adaptive Biotechnologies Corporation
$17.36
+$0.66(+3.95%)
62
Overall
40
Value
83
Tech
65
Quality
Market Cap
$2.03B
Volume
2.22M
52W Range
$9.90 - $20.76
Target Price
$20.14
Order:
Income Statement
| Metric | Trend | Chart | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Total Revenue | $85.1M | $98.4M | $154.3M | $185.3M | $170.3M | $179.0M | $277.0M | ||
| Total Revenue | $85.1M | $98.4M | $154.3M | $185.3M | $170.3M | $179.0M | $277.0M | ||
| COST OF GOODS SOLD | |||||||||
| Cost of Revenue | $22.3M | $22.5M | $49.3M | $57.9M | $75.6M | $72.1M | $71.4M | ||
| GROSS PROFIT | |||||||||
| Gross Profit | $62.8M | $75.9M | $105.0M | $127.4M | $94.7M | $106.9M | $205.6M | ||
| OPERATING EXPENSES | |||||||||
| Operating Expenses | $141.2M | $228.7M | $314.0M | $327.6M | $296.3M | $262.2M | $262.7M | ||
| Research & Development | $70.7M | $116.1M | $142.3M | $141.8M | $122.1M | $103.0M | $93.8M | ||
| Research Expense | $70.7M | $116.1M | $142.3M | $141.8M | $122.1M | $103.0M | $93.8M | ||
| Selling, General & Administrative | $68.8M | $110.9M | $170.0M | $184.1M | $172.5M | $157.6M | $167.3M | ||
| Selling & Marketing Expenses | $38.5M | $61.4M | $95.5M | $95.6M | $88.6M | $84.8M | $94.6M | ||
| General & Administrative Expenses | $30.3M | $49.5M | $74.5M | $88.5M | $83.9M | $72.8M | $72.7M | ||
| Promotion & Advertising | $6.6M | $14.5M | $22.4M | -- | -- | -- | -- | ||
| Salaries & Wages | -- | -- | -- | -- | -- | -- | $51.5M | ||
| Depreciation & Amortization | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | ||
| Depreciation & Amortization | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | ||
| Amortization | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | ||
| Other Operating Expenses | $-800.0K | $-1.4M | $-3.4M | -- | -- | -- | -- | ||
| OPERATING INCOME | |||||||||
| Operating income | $-78.4M | $-152.8M | $-209.0M | $-200.2M | $-227.0M | $-162.5M | $-57.1M | ||
| EBITDA | $-65.3M | $-144.3M | $-193.3M | $-175.2M | $-189.3M | $-128.7M | $-29.9M | ||
| NON-OPERATING ITEMS | |||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | $4.2M | $13.8M | $11.6M | $11.8M | ||
| Intinc | $9.8M | $6.6M | $1.7M | $4.1M | $15.5M | $14.5M | $9.4M | ||
| Net Non-Operating Interest Income/Expense | $9.8M | $6.6M | $1.7M | $-182.0K | $1.7M | $3.0M | $-2.3M | ||
| Other Income/Expense | $2.3M | $69.8M | $95.8M | $99.4M | $25.4M | $7.2M | -- | ||
| Other Special Charges | $-2.3M | $-69.8M | $-95.8M | -- | -- | -- | -- | ||
| SPECIAL ITEMS | |||||||||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | $25.4M | $7.2M | -- | ||
| PRE-TAX INCOME | |||||||||
| EBIT | $-68.6M | $-152.8M | $-207.3M | $-196.1M | $-211.5M | $-148.0M | $-47.7M | ||
| Pre-Tax Income | $-68.6M | $-146.2M | $-207.3M | $-200.4M | $-225.3M | $-159.6M | $-59.5M | ||
| INCOME TAX | |||||||||
| Tax Provision | $2.1M | -- | -- | -- | -- | -- | $-3.0K | ||
| NET INCOME | |||||||||
| Net Income | $-68.6M | $-146.2M | $-207.3M | $-200.2M | $-225.3M | $-159.5M | $-59.5M | ||
| Net Income (Continuing Operations) | $-68.6M | $-146.2M | $-207.3M | $-200.4M | $-225.3M | $-159.6M | $-59.5M | ||
| Net Income (Discontinued Operations) | $-68.6M | $-146.2M | $-207.3M | $-200.2M | $-225.3M | $-159.5M | $-59.5M | ||
| Net Income (Common Stockholders) | $-69.6M | $-146.2M | $-207.3M | $-200.2M | $-225.3M | $-159.5M | $-59.5M | ||
| TOTALS | |||||||||
| Total Expenses | $163.5M | $251.2M | $363.3M | $385.5M | $371.9M | $334.3M | $334.1M | ||
| SHARE & EPS DATA | |||||||||
| Average Shares Outstanding | $69.2M | $131.2M | $140.4M | $142.5M | $144.4M | $147.1M | $151.7M | ||
| Average Shares Outstanding (Diluted) | $69.2M | $131.2M | -- | $142.5M | $144.4M | $147.1M | $151.7M | ||
| Shares Outstanding | $126.3M | $139.2M | $141.6M | $143.2M | $145.1M | $148.6M | $154.0M | ||
| Basic EPS | $-1.01 | $-1.11 | $-1.48 | $-1.4 | $-1.56 | $-1.08 | $-0.39 | ||
| Basic EPS (Continuing Operations) | $-1.01 | $-1.11 | $-1.48 | $-1.4 | $-1.56 | $-1.08 | $-0.39 | ||
| Diluted EPS | $-1.01 | $-1.11 | $-1.48 | $-1.4 | $-1.56 | $-1.08 | $-0.39 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-1.4 | $-1.56 | $-1.08 | $-0.39 | ||
| OTHER METRICS | |||||||||
| Accretion On Preferred Stock | $964.0K | -- | -- | -- | -- | -- | -- | ||
| Minority Interests | -- | $743.3M | $19.0K | $177.0K | $54.0K | $103.0K | $-42.0K | ||
| Other Gand A | $30.3M | $49.5M | $74.5M | $88.5M | $83.9M | $72.8M | $72.7M | ||
| Preferred Stock Dividends | $964.0K | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $5.3M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ADPT | $17.36 | +4.0% | 2.22M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Adaptive Biotechnologies Corporation Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW